Sentences with phrase «ai programs in future»

Meanwhile, AMD was rumored to be working with Tesla a custom chip to run the AI programs in future self - driving electric cars.

Not exact matches

Important factors that could cause actual results to differ materially from those reflected in such forward - looking statements and that should be considered in evaluating our outlook include, but are not limited to, the following: 1) our ability to continue to grow our business and execute our growth strategy, including the timing, execution, and profitability of new and maturing programs; 2) our ability to perform our obligations under our new and maturing commercial, business aircraft, and military development programs, and the related recurring production; 3) our ability to accurately estimate and manage performance, cost, and revenue under our contracts, including our ability to achieve certain cost reductions with respect to the B787 program; 4) margin pressures and the potential for additional forward losses on new and maturing programs; 5) our ability to accommodate, and the cost of accommodating, announced increases in the build rates of certain aircraft; 6) the effect on aircraft demand and build rates of changing customer preferences for business aircraft, including the effect of global economic conditions on the business aircraft market and expanding conflicts or political unrest in the Middle East or Asia; 7) customer cancellations or deferrals as a result of global economic uncertainty or otherwise; 8) the effect of economic conditions in the industries and markets in which we operate in the U.S. and globally and any changes therein, including fluctuations in foreign currency exchange rates; 9) the success and timely execution of key milestones such as the receipt of necessary regulatory approvals, including our ability to obtain in a timely fashion any required regulatory or other third party approvals for the consummation of our announced acquisition of Asco, and customer adherence to their announced schedules; 10) our ability to successfully negotiate, or re-negotiate, future pricing under our supply agreements with Boeing and our other customers; 11) our ability to enter into profitable supply arrangements with additional customers; 12) the ability of all parties to satisfy their performance requirements under existing supply contracts with our two major customers, Boeing and Airbus, and other customers, and the risk of nonpayment by such customers; 13) any adverse impact on Boeing's and Airbus» production of aircraft resulting from cancellations, deferrals, or reduced orders by their customers or from labor disputes, domestic or international hostilities, or acts of terrorism; 14) any adverse impact on the demand for air travel or our operations from the outbreak of diseases or epidemic or pandemic outbreaks; 15) our ability to avoid or recover from cyber-based or other security attacks, information technology failures, or other disruptions; 16) returns on pension plan assets and the impact of future discount rate changes on pension obligations; 17) our ability to borrow additional funds or refinance debt, including our ability to obtain the debt to finance the purchase price for our announced acquisition of Asco on favorable terms or at all; 18) competition from commercial aerospace original equipment manufacturers and other aerostructures suppliers; 19) the effect of governmental laws, such as U.S. export control laws and U.S. and foreign anti-bribery laws such as the Foreign Corrupt Practices Act and the United Kingdom Bribery Act, and environmental laws and agency regulations, both in the U.S. and abroad; 20) the effect of changes in tax law, such as the effect of The Tax Cuts and Jobs Act (the «TCJA») that was enacted on December 22, 2017, and changes to the interpretations of or guidance related thereto, and the Company's ability to accurately calculate and estimate the effect of such changes; 21) any reduction in our credit ratings; 22) our dependence on our suppliers, as well as the cost and availability of raw materials and purchased components; 23) our ability to recruit and retain a critical mass of highly - skilled employees and our relationships with the unions representing many of our employees; 24) spending by the U.S. and other governments on defense; 25) the possibility that our cash flows and our credit facility may not be adequate for our additional capital needs or for payment of interest on, and principal of, our indebtedness; 26) our exposure under our revolving credit facility to higher interest payments should interest rates increase substantially; 27) the effectiveness of any interest rate hedging programs; 28) the effectiveness of our internal control over financial reporting; 29) the outcome or impact of ongoing or future litigation, claims, and regulatory actions; 30) exposure to potential product liability and warranty claims; 31) our ability to effectively assess, manage and integrate acquisitions that we pursue, including our ability to successfully integrate the Asco business and generate synergies and other cost savings; 32) our ability to consummate our announced acquisition of Asco in a timely matter while avoiding any unexpected costs, charges, expenses, adverse changes to business relationships and other business disruptions for ourselves and Asco as a result of the acquisition; 33) our ability to continue selling certain receivables through our supplier financing program; 34) the risks of doing business internationally, including fluctuations in foreign current exchange rates, impositions of tariffs or embargoes, compliance with foreign laws, and domestic and foreign government policies; and 35) our ability to complete the proposed accelerated stock repurchase plan, among other things.

Steven Cook, senior fellow for Middle East and Africa Studies at the Council on Foreign Relations, said higher oil prices lessen all the worries from 2015 and 2016 about the Saudi government's ability to maintain its commitments, but the consolidation of power in the hands of the Crown Prince also is significant for the market and investors as his reform program is widely regarded as critical for Saudi Arabia's future prosperity.

Seeing as even the tiniest hint of future plans uttered by Bernanke in 2013 had the power to move markets, all eyes and ears will be on Yellen as the Fed continues to make adjustments to its economic stimulus program.

Having founded a video game company, and with major investments in an eyewear company, Piqué is increasingly involved in business strategy himself; in 2017 he underwent an executive program at Harvard Business School, and he says he hopes to run Barça in the future, after he finally retires from football, probably in a few years» time.

The hope is that by focusing their efforts on applicants most likely to be future leaders in their respective countries, even a small program might be able to impact relations between nations.

Its electrical engineering program offers a unique specialization in nanoengineering, which (depending on whom you ask) may be the future of telecommunications.

King may not agree that sports is the most valuable appointment programming available today, but the growing trend of longer - term broadcast deals forces him to plan for a future where sport's dominance in delivering a live audience is the reality.

Aldred was hired in the late 1990s directly out of the robotics program at the University of Kent, Canterbury, to help prepare for the robotic future.

«I'm asking a lot of these garments,» said Yang, «I want this program to be the leader of where uniforms can go in the future.

But there's hope that there will be some openings in the future — a wave of retirement is approaching and the pool of candidates graduating from related programs is expected to shrink from 300 in 2016 to only 200 per year until 2022.

Above all, the analysts were interested in the future of the Roll Up the Rim customer loyalty program, which cut into sales this year after odds for prize payouts were increased to 1 in 6 to celebrate the promotion's 25th anniversary.

I had a chance to chat with Marni Shulman, Shomi's head of content and programming, about the service's first few months and where it's going in the future.

With an early success on its hands, Econet is staking much of its future growth in Zimbabwe — and other African countries in which it does business including Nigeria, South Africa, and Botswana — on non-voice revenues that come from programs like EcoCash.

Airbus has a new senior management team coming on board in early 2019 and Myerson said that while it will be expected to address the future of the A380, investors will be focused more on the success of the A320 and A350 programs.

And insiders say the company has commissioned two consulting groups to look for $ 100 million in savings that McDonald's can then put toward digital initiatives and a program the company is grandly calling «Experience of the Future.»

«No one knows exactly what this new program is going to look like in the future,» he said.

Once you have registered in an amnesty program, all sales tax issues your company faces in the future will be under state scrutiny, says Paul N. Gada, senior small - business tax analyst with CCH Business Owner's Toolkit, a division of CCH Tax and Accounting in Riverwoods, Illinois.

The ORPP was billed Thursday as a mandatory plan that will be modelled on the CPP and could be absorbed into the national program if the federal government agreed to a CPP enhancement in the future.

The next day, Russian officials announced they were halting the Future Leaders Exchange Program, in which American and Russian teenagers spend a year in each other's countries.

Many people argue about what needs to come first in order to create an entrepreneurial community — ideas or capital — but it's a chicken - and - egg debate, says Brad Whitehead, president of the Fund For Our Economic Future, a program that pools funding for entrepreneurs from various philanthropic organizations across Northeast Ohio.

Entrepreneurs and investors are betting on a future full of flying robots that can be programmed to do anything from survey crops or wildlife to delivering vaccines to remote villages in Africa.

«So proper investment in doing more polling but coupling that with a data science program is really going to be the future.»

These forward - looking statements include, among other things, statements about full - year 2018 guidance, project milestones, increased opportunities in the market, backlog, bids and change orders outstanding, target projects and revenue opportunity pipeline, to the extent these may be viewed as indicators of future revenues or profitability, the expected impacts of the F2G program and progress toward completing the proposed combination with CB&I and the anticipated benefits of that transaction.

He added it's possible the program's biomarkers will be changed to «superior alternative ones» in the future.

It's possible you may be able to find Nest products on Amazon in the future through Amazon's Marketplace program, which lets third - party retailers sell items through Amazon.

With the future of the travel ban still uncertain, applicants to the EB - 5 program are now rushing in, hoping to get approved before any new executive orders.

Secondly, research also indicates that previous success of the incubator and firms in its program is one of the best predictors of success for future firms in the same program.

Even with local programs like the one being launched in New York, a future in which most workplaces are holding meetings in virtual reality and using holograms to work on a 3D model is still far off.

With these kind of numbers in mind, it's clear that adding some coding know - how to your toolkit is a wise investment in your career future, whether or not you're specifically interested in developer roles — since having programming skills means you can work in virtually any field.

What's more, Hartsock fears the program will change further, prompting even more serious business shifts in the future.

However, McKenzie acknowledged elements of Syria's chemical weapons program remain and he could not guarantee that Syria would be unable to conduct a chemical attack in the future.

These risks and uncertainties include: Gilead's ability to achieve its anticipated full year 2018 financial results; Gilead's ability to sustain growth in revenues for its antiviral and other programs; the risk that private and public payers may be reluctant to provide, or continue to provide, coverage or reimbursement for new products, including Vosevi, Yescarta, Epclusa, Harvoni, Genvoya, Odefsey, Descovy, Biktarvy and Vemlidy ®; austerity measures in European countries that may increase the amount of discount required on Gilead's products; an increase in discounts, chargebacks and rebates due to ongoing contracts and future negotiations with commercial and government payers; a larger than anticipated shift in payer mix to more highly discounted payer segments and geographic regions and decreases in treatment duration; availability of funding for state AIDS Drug Assistance Programs (ADAPs); continued fluctuations in ADAP purchases driven by federal and state grant cycles which may not mirror patient demand and may cause fluctuations in Gilead's earnings; market share and price erosion caused by the introduction of generic versions of Viread and Truvada, an uncertain global macroeconomic environment; and potential amendments to the Affordable Care Act or other government action that could have the effect of lowering prices or reducing the number of insured patients; the possibility of unfavorable results from clinical trials involving investigational compounds; Gilead's ability to initiate clinical trials in its currently anticipated timeframes; the levels of inventory held by wholesalers and retailers which may cause fluctuations in Gilead's earnings; Kite's ability to develop and commercialize cell therapies utilizing the zinc finger nuclease technology platform and realize the benefits of the Sangamo partnership; Gilead's ability to submit new drug applications for new product candidates in the timelines currently anticipated; Gilead's ability to receive regulatory approvals in a timely manner or at all, for new and current products, including Biktarvy; Gilead's ability to successfully commercialize its products, including Biktarvy; the risk that physicians and patients may not see advantages of these products over other therapies and may therefore be reluctant to prescribe the products; Gilead's ability to successfully develop its hematology / oncology and inflammation / respiratory programs; safety and efficacy data from clinical studies may not warrant further development of Gilead's product candidates, including GS - 9620 and Yescarta in combination with Pfizer's utomilumab; Gilead's ability to pay dividends or complete its share repurchase program due to changes in its stock price, corporate or other market conditions; fluctuations in the foreign exchange rate of the U.S. dollar that may cause an unfavorable foreign currency exchange impact on Gilead's future revenues and pre-tax earnings; and other risks identified from time to time in Gilead's reports filed with the U.S. Securities and Exchange Commission (tprograms; the risk that private and public payers may be reluctant to provide, or continue to provide, coverage or reimbursement for new products, including Vosevi, Yescarta, Epclusa, Harvoni, Genvoya, Odefsey, Descovy, Biktarvy and Vemlidy ®; austerity measures in European countries that may increase the amount of discount required on Gilead's products; an increase in discounts, chargebacks and rebates due to ongoing contracts and future negotiations with commercial and government payers; a larger than anticipated shift in payer mix to more highly discounted payer segments and geographic regions and decreases in treatment duration; availability of funding for state AIDS Drug Assistance Programs (ADAPs); continued fluctuations in ADAP purchases driven by federal and state grant cycles which may not mirror patient demand and may cause fluctuations in Gilead's earnings; market share and price erosion caused by the introduction of generic versions of Viread and Truvada, an uncertain global macroeconomic environment; and potential amendments to the Affordable Care Act or other government action that could have the effect of lowering prices or reducing the number of insured patients; the possibility of unfavorable results from clinical trials involving investigational compounds; Gilead's ability to initiate clinical trials in its currently anticipated timeframes; the levels of inventory held by wholesalers and retailers which may cause fluctuations in Gilead's earnings; Kite's ability to develop and commercialize cell therapies utilizing the zinc finger nuclease technology platform and realize the benefits of the Sangamo partnership; Gilead's ability to submit new drug applications for new product candidates in the timelines currently anticipated; Gilead's ability to receive regulatory approvals in a timely manner or at all, for new and current products, including Biktarvy; Gilead's ability to successfully commercialize its products, including Biktarvy; the risk that physicians and patients may not see advantages of these products over other therapies and may therefore be reluctant to prescribe the products; Gilead's ability to successfully develop its hematology / oncology and inflammation / respiratory programs; safety and efficacy data from clinical studies may not warrant further development of Gilead's product candidates, including GS - 9620 and Yescarta in combination with Pfizer's utomilumab; Gilead's ability to pay dividends or complete its share repurchase program due to changes in its stock price, corporate or other market conditions; fluctuations in the foreign exchange rate of the U.S. dollar that may cause an unfavorable foreign currency exchange impact on Gilead's future revenues and pre-tax earnings; and other risks identified from time to time in Gilead's reports filed with the U.S. Securities and Exchange Commission (tPrograms (ADAPs); continued fluctuations in ADAP purchases driven by federal and state grant cycles which may not mirror patient demand and may cause fluctuations in Gilead's earnings; market share and price erosion caused by the introduction of generic versions of Viread and Truvada, an uncertain global macroeconomic environment; and potential amendments to the Affordable Care Act or other government action that could have the effect of lowering prices or reducing the number of insured patients; the possibility of unfavorable results from clinical trials involving investigational compounds; Gilead's ability to initiate clinical trials in its currently anticipated timeframes; the levels of inventory held by wholesalers and retailers which may cause fluctuations in Gilead's earnings; Kite's ability to develop and commercialize cell therapies utilizing the zinc finger nuclease technology platform and realize the benefits of the Sangamo partnership; Gilead's ability to submit new drug applications for new product candidates in the timelines currently anticipated; Gilead's ability to receive regulatory approvals in a timely manner or at all, for new and current products, including Biktarvy; Gilead's ability to successfully commercialize its products, including Biktarvy; the risk that physicians and patients may not see advantages of these products over other therapies and may therefore be reluctant to prescribe the products; Gilead's ability to successfully develop its hematology / oncology and inflammation / respiratory programs; safety and efficacy data from clinical studies may not warrant further development of Gilead's product candidates, including GS - 9620 and Yescarta in combination with Pfizer's utomilumab; Gilead's ability to pay dividends or complete its share repurchase program due to changes in its stock price, corporate or other market conditions; fluctuations in the foreign exchange rate of the U.S. dollar that may cause an unfavorable foreign currency exchange impact on Gilead's future revenues and pre-tax earnings; and other risks identified from time to time in Gilead's reports filed with the U.S. Securities and Exchange Commission (tprograms; safety and efficacy data from clinical studies may not warrant further development of Gilead's product candidates, including GS - 9620 and Yescarta in combination with Pfizer's utomilumab; Gilead's ability to pay dividends or complete its share repurchase program due to changes in its stock price, corporate or other market conditions; fluctuations in the foreign exchange rate of the U.S. dollar that may cause an unfavorable foreign currency exchange impact on Gilead's future revenues and pre-tax earnings; and other risks identified from time to time in Gilead's reports filed with the U.S. Securities and Exchange Commission (the SEC).

Leveraging the expertise of all of the partners, the goals of this program are to better position Ameren to meet its customers» future energy needs and expectations, create new jobs through these start - up companies and provide university students opportunities to be more engaged in the energy business.

The silver lining is that beginning this week, the entire complicated system of itemized deductions will only benefit 5 % of tax filers which should make it much easier to eliminate them entirely in the future, (to be replaced with much better targeted spending programs in my parallel rational Congress delusion), since 95 % of Americans won't benefit from itemized deductions.

The increase in program expenses was primarily the result of the inclusion in the August 2012 financial results of «an updated accrual estimate for employee and veterans» future employee benefits based on accrual valuations prepared for the Government's 2011 - 12 financial statements».

Illinois's solar market under the Future Energy Jobs Act is just getting started, but a business group is calling for the next governor and state legislature to provide less restriction and more action in community and distributed solar programs.

(a) Schedule 2.7 (a) of the Disclosure Schedule contains a list setting forth each employee benefit plan, program, policy or arrangement (including any «employee benefit plan» as defined in Section 3 (3) of the Employee Retirement Income Security Act of 1974, as amended («ERISA»)(«ERISA Plan»)-RRB-, including, without limitation, employee pension benefit plans, as defined in Section 3 (2) of ERISA, multi-employer plans, as defined in Section 3 (37) of ERISA, employee welfare benefit plans, as defined in Section 3 (1) of ERISA, deferred compensation plans, stock option plans, bonus plans, stock purchase plans, fringe benefit plans, life, hospitalization, disability and other insurance plans, severance or termination pay plans and policies, sick pay plans and vacation plans or arrangements, whether or not an ERISA Plan (including any funding mechanism therefore now in effect or required in the future as a result of the transactions contemplated by this Agreement or otherwise), whether formal or informal, oral or written, under which (i) any current or former employee, director or individual consultant of the Company (collectively, the «Company Employees») has any present or future right to benefits and which are contributed to, sponsored by or maintained by the Company or (ii) the Company or any ERISA Affiliate (as hereinafter defined) has had, has or may have any actual or contingent present or future liability or obligation.

We have argued in previous articles that spending by governments on public infrastructure that would provide services to Canadians for many decades in the future is not the same as spending by governments on programs and services that only benefit current generations.

Whether through direct connections that the Edison Awards facilitates to these audiences, or as a part of educational assets developed by Edison Universe, award winners are encouraged to give back to current and future innovators through storytelling, mentorship programs, direct teaching and communication in a variety of media.

There is no prediction that can be made as to what will take place with any of the student loan forgiveness programs, but borrowers should be aware that any or all of these benefits may disappear in the future, leaving the responsibility to repay student loans fully on their shoulders.

When I'm 65 is a groundbreaking national documentary and engagement program focusing on the realities of retirement in the 21st century and the financial choices that all Americans need to make to plan for a financially secure future.

An example of a program carrying out this work is Ryerson Futures — an accelerator program that works with startups based out of Toronto that moves past the idea of looking to Asia as only a source for investment, but rather for spaces of collaboration and growth in new markets.

Direct program expenses were up $ 1.0 billion (5.5 %), primarily due to the timing of payments as well as an increase in federal government employee pension and other future benefit liabilities, reflecting the impact of lower interest rates.

Use it to attend next year's live program in Panama or any future conference you may be interested in.

Mind you, Environment Minister Peter Kent allowed in May that a continental cap - and - trade program «can always be something to consider in the future.»

We are pleased to share the news that our Head of Regulatory Relations Ryan Zagone has been included in this year's BAFT Future Leaders Program.

Under Pension Fund Capitalism, employees are encouraged to think of themselves as capitalists in miniature — and provide for their retirement by employee stock ownership programs rather than saving up their wages themselves or having pensions financed on a pay - as - you - go basis out of future production.

With the ending of the stimulus programs, such large lapses are not expected in the future.

We are building a future in which the cost and complexity of satellite programs are no longer barriers to accessing information about the Earth.